1-3 of 3
P. Joy Ho, MBBS, DPhil, FRACP, FRCPA, FFSc(RCPA)
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM): Updated Efficacy and Safety Analysis of Pollux

Meletios A. Dimopoulos, Darrell J. White, MD, Lofti Benboubker, MD, Gordon Cook, MD PhD, Merav Leiba, James Morton, P. Joy Ho, MBBS, DPhil, FRACP, FRCPA, FFSc(RCPA), Kihyun Kim, Naoki Takezako, MD PhD, Sonali Trivedi, Kaida Wu, Tineke Casneuf, Christopher Chiu, Jordan Schecter, Philippe Moreau, MDPhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 739.
https://doi.org/10.1182/blood.V130.Suppl_1.739.739
Published: 2017
Journal Articles

Primary Analysis of Juliet: A Global, Pivotal, Phase 2 Trial of CTL019 in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Stephen J. Schuster, MD, Michael R. Bishop, MD, Constantine S. Tam, MBBS, MD FRACP, FRCPA, Edmund K. Waller, MD, Peter Borchmann, MD, Joseph P. McGuirk, DO, Ulrich Jaeger, MD, Samantha Jaglowski, MD, Charalambos Andreadis, MD MSCE, Jason R. Westin, MD, Isabelle Fleury, MD MSc, FRCPC, Veronika Bachanova, MD PhD, Stephen Ronan Foley, MD FRCPC, P. Joy Ho, MBBS, DPhil, FRACP, FRCPA, FFSc(RCPA), Stephan Mielke, MD, John M. Magenau, MD, Harald Holte, Koen Van Besien, MD PhD, Marie Jose Kersten, MD PhD, Takanori Teshima, MD PhD, Kensei Tobinai, MD PhD, Paolo Corradini, MD, Oezlem Anak, MD, Lida Bubuteishvili Pacaud, MD, Christopher del Corral, PharmaD, Rakesh Awasthi, PhD, Feng Tai, PhD, Gilles Salles, MD PhD, Richard Thomas Maziarz, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 577.
https://doi.org/10.1182/blood.V130.Suppl_1.577.577
Published: 2017
Journal Articles

Overall Survival of Patients with Relapsed Multiple Myeloma Treated with Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone According to Prior Line of Therapy and Previous Exposure to Bortezomib: Secondary Analysis of the Phase 3 Endeavor Study

Katja C. Weisel, David Siegel, MD PhD, Jesus F. San Miguel, MD, Roman Hájek, MD, P. Joy Ho, MBBS, DPhil, FRACP, FRCPA, FFSc(RCPA), Gianluca Gaidano, MD PhD, Robert Z. Orlowski, MD PhD, Lifen Zhou, Amy S. Kimball, Philippe Moreau, MDPhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1850.
https://doi.org/10.1182/blood.V130.Suppl_1.1850.1850
Published: 2017